cancer immunity Flashcards
what cells give a good prognosis
CD8+ cells, TLS and M1
what cells give a bad prognosis
M2 and Treg due to a immunosuppressive role
what is the function of the antigen processing machinery
that proteins of the cell are destroyed into smaller peptides and get loaded onto HLA/MHC class 1 which presents the peptides to the CD8 T cel
oncofoetal proteins
proteins that are normally expressed during embryology but are now being expressed by the tumor
neo antigen
somatic mutation has lead to the making of non self proteins or antigens
cross presentation
dendritic cells load peptides/antigens derived from exogenous route onto HLA class 1 molecules
what happens in the main killing pathway when a CD8+ cytotoxic T cell binds to a transformed cell
the t cell will start to produce perforin and granzyme B which will produce pores in the cell membrane of the bad cell and cause apoptosis
explain FAS-FASL interaction
this is the non main pathway of killing a transformed cell by T cell. FAS-FASL will interact and activate caspase 8 which will active caspase cascades and this will lead to cell death
why are anti tumor immune responses desirably dominated by TH1 type CD4 responses
because these will produce pro inflammaitory cytokines like IL12 and IFN-y which will promote tumor immunity.
which signals proliferate T0 cells into Treg cells
TGF-B and IL-2
in which two pathways can a tumor escape the immune system
PD-L1 expression in tumor
immune suppresed microenvironmend
explain the working of PD-L1
PD-L1 is a ligand that binds and transmits a negative signal to T cells which causes T cells to become inhibited. the effect is loss of HLA/MHC class 1
what normaly happens when MHC class1 is lost
NK cells will recognize that MHC class 1 is lost and cause lysis. however this is dependend on ligands in the tumor, these ligands can be lost and then the NK will not come into action
what are tumours with a high mutation rate
polymerase mutatns (POLE) and mismatch repair deficient tumours
which tumours often have a HLA class 1 defect
MMRdeficient tumours